SKI pathways inducing progression of human melanoma

Cancer and Metastasis Reviews

Volumn 24, Issue 2, 2005, Pages 265-272

  Reed, Jon A ^a   Lin, Qiushi ^a   Chen, Dahu ^a   Mian, I Saira ^b   Medrano, Estela E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

catenin; FHL2; SKI; TGF

Indexed keywords

BETA CATENIN; BINDING PROTEIN; BIOCHEMICAL MARKER; HISTONE ACETYLTRANSFERASE PCAF; NUCLEAR PROTEIN; PROTEIN SKI; RETINOBLASTOMA PROTEIN; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CYTOPLASM; DNA REPLICATION; DOWN REGULATION; GENE MAPPING; GENE MUTATION; GENE REPRESSION; GENETIC SCREENING; HUMAN; MELANOCYTE; MELANOMA; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; MELANOMA; MICE; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 21544439320     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-005-1576-x     Document Type: Article

References (58)

1. Colmenares C, Stavnezer E: Structure and activities of the ski oncogene. Semin Cancer Biol 1: 383-387, 1990
2. Nicol R, Zheng G, Sutrave P, Foster DN, Stavnezer E: Association of specific DNA binding and transcriptional repression with the transforming and myogenic activities of c-Ski. Cell Growth Differ 10: 243-254, 1999
3. Medrano EE: Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: Consequences for proliferation, survival, and metastasis. Oncogene 22: 3123-3129, 2003.
4. Harada J, Kokura K, Kanei-Ishii C, Nomura T, Khan MM, Kim Y, Ishii S: Requirement of the co-repressor homeodomain-interacting protein kinase 2 for ski-mediated inhibition of bone morphogenetic protein-induced transcriptional activation. J Biol Chem 278: 38998-39005, 2003.
5. Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, Kuhl M, Behrens J, Von Der MK, Starzinski-Powitz A, Wixler V: The LIM-only protein FHL2 interacts with {beta}-catenin promotes differentiation of mouse myoblasts. J Cell Biol 159: 113-122, 2002
6. Wei Y, Renard CA, Labalette C, Wu Y, Levy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA: Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem 278: 5188-5194, 2003
7. Wilson JJ, Malakhova M, Zhang R, Joachimiak A, Hegde RS: Crystal structure of the dachshund homology domain of human SKI. Structure (Camb) 12: 785-792, 2004
8. Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D, Medrano EE: Cytoplasmic localization of the oncogenic protein ski in human cutaneous melanomas in vivo: Functional implications for transforming growth factor Beta signaling. Cancer Res 61: 8074-8078, 2001
9. Fukuchi M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H: Increased expression of c-Ski as a co-repressor in transforming growth factor-beta signaling correlates with progression of esophageal squamous cell carcinoma. Int J Cancer 108: 818-824, 2004
10. Fujimoto T, Nishikawa A, Iwasaki M, Akutagawa N, Teramoto M, Kudo R: Gene expression profiling in two morphologically different uterine cervical carcinoma cell lines derived from a single donor using a human cancer cDNA array. Gynecol Oncol 93: 446-453, 2004
11. Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, Rochlitz C: Amplification of SKI is a prognostic marker in early colorectal cancer. Neoplasia 6: 207-212, 2004
12. Zhang F, Lundin M, Ristimaki A, Heikkila P, Lundin J, Isola J, Joensuu H, Laiho M: Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res 63: 5005-5010, 2003
13. Nomura T, Tanikawa J, Akimaru H, Kanei-Ishii C, Ichikawa-Iwata E, Khan MM, Ito H, Ishii S: Oncogenic activation of c-Myb correlates with a loss of negative regulation by TIF1beta and Ski. J Biol Chem 279: 16715-16726, 2004
14. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM: Novel therapies for chronic myelogenous leukemia. Exp Hematol 29: 543-556, 2001
15. Funato T, Satou J, Kozawa K, Fujimaki S, Miura T, Kaku M: Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin. Oncol Rep 8: 807-810, 2001
16. Fumagalli S, Doneda L, Nomura N, Larizza L: Expression of the c-ski proto-oncogene in human melanoma cell lines. Melanoma Res 3: 23-27, 1993
17. Kokura K, Kim H, Shinagawa T, Khan MM, Nomura T, Ishii S: The Ski-binding protein C184M negatively regulates tumor growth factor-beta signaling by sequestering the Smad proteins in the cytoplasm. J Biol Chem 278: 20133-20139, 2003
18. Wei Y, Renard CA, Labalette C, Wu Y, Levy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia, MA: Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem 278: 5188-5194, 2003
19. Xu W, Angelis K, Danielpour D, Haddad MM, Bischof O, Campisi J, Stavnezer E, Medrano EE: Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci USA 97: 5924-5929, 2000
20. Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700, 2003
21. Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178, 2000
22. Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K, Kawabata M: c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem 274: 35269-35277, 1999
23. Prunier C, Pessah M, Ferrand N, Seo SR, Howe P, Atfi A: The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation. J Biol Chem 278: 26249-26257, 2003
24. Suzuki H, Yagi K, Kondo M, Kato M, Miyazono K, Miyazawa K: c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements. Oncogene 2004
25. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R: V599EB-RAF is an oncogene in melanocytes. Cancer Res 64: 2338-2342, 2004
26. Tokitou F, Nomura T, Khan MM, Kaul SC, Wadhwa R, Yasukawa T, Kohno I, Ishii S: Viral ski inhibits retinoblastoma protein (Rb)-mediated transcriptional repression in a dominant negative fashion. J Biol Chem 274: 4485-4488, 1999
27. Prathapam T, Kuhne C, Banks L: Skip interacts with the retinoblastoma tumor suppressor and inhibits its transcriptional repression activity. Nucleic Acids Res 30: 5261-5268, 2002
28. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T, Ichikawa-Iwata E, Zhong S, Pandolfi PP, Ishii S: Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell 7: 1233-1243, 2001
29. Yang FC, Merlino G, Chin L: Genetic dissection of melanoma pathways in the mouse. Semin Cancer Biol 11: 261-268, 2001
30. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L: Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 21: 2144-2153, 2001
31. Tietze MK, Chin L: Murine models of malignant melanoma. Mol Med Today 6: 408-410, 2000
32. Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, Ishii S, Stavnezer E, Campisi J, Fisher DE, Ben Ze'ev A, Medrano EE: SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 63: 6626-6634, 2003
33. El Mourabit H, Muller S, Tunggal L, Paulsson M, Aumailley M: Analysis of the adaptor function of the LIM domain-containing protein FHL2 using an affinity chromatography approach. J Cell Biochem 92: 612-625, 2004
34. Schmeichel KL, Beckerle MC: Molecular dissection of a LIM domain. Mol Biol Cell 8: 219-230, 1997
35. Dawid IB, Breen JJ, Toyama R: LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet 14: 156-162, 1998
36. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schule R: FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 19: 359-369, 2000
37. Chan KK, Tsui SK, Ngai SM, Lee SM, Kotaka M, Waye MM, Lee CY, Fung KP: Protein-protein interaction of FHL2, a LIM domain protein preferentially expressed in human heart, with hCDC47. J Cell Biochem 76: 499-508, 2000
38. Tanahashi H, Tabira T: Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM- domain protein. Hum Mol Genet 9: 2281-2289, 2000
39. Dye BT, Patton JG: An RNA recognition motif (RRM) is required for the localization of PTB-associated splicing factor (PSF) to subnuclear speckles. Exp Cell Res 263: 131-144, 2001
40. Ng EK, Chan KK, Wong CH, Tsui SK, Ngai SM, Lee SM, Kotaka M, Lee CY, Waye MM, Fung KP: Interaction of the heart-specific LIM domain protein, FHL2, with DNA-binding nuclear protein, hNP220. J Cell Biochem 84: 556-566, 2002
41. Stilo R, Leonardi A, Formisano L, Di Jeso B, Vito P, Liguoro D: TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation. FEBS Lett 521: 165-169, 2002
42. McLoughlin P, Ehler E, Carlile G, Licht JD, Schafer BW: The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein. J Biol Chem 277: 37045-37053, 2002
43. Lange S, Auerbach D, McLoughlin P, Perriard E, Schafer BW, Perriard JC, Ehler E: Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci 115: 4925-4936, 2002
44. Yan J, Zhu J, Zhong H, Lu Q, Huang C, Ye Q: BRCA1 interacts with FHL2 and enhances FHL2 transactivation function. FEBS Lett 553: 183-189, 2003
45. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schafer BW: DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol 151: 495-506, 2000
46. Widlund HR, Fisher DE: Microphthalamia-associated transcription factor: A critical regulator of pigment cell development and survival. Oncogene 22: 3035-3041, 2003
47. Goding CR: Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 14: 1712-1728, 2000
48. Yasumoto K, Takeda K, Saito H, Watanabe K, Takahashi K, Shibahara S: Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. EMBO J 21: 2703-2714, 2002
49. Chu W, Pak BJ, Bani MR, Kapoor M, Lu SJ, Tamir A, Kerbel RS, Ben David Y: Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene 19: 395-402, 2000
50. Conacci-Sorrell ME, Ben Yedidia T, Shtutman M, Feinstein E, Einat P, Ben Ze'ev A: Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 16: 2058-2072, 2002
51. Siegel PM, Massague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821, 2003
52. Rodeck U, Nishiyama T, Mauviel A: Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res 59: 547-550, 1999
53. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, Herlyn M: Transforming Growth Factor-beta1 Increases Survival of Human Melanoma through Stroma Remodeling. Cancer Res 61: 8306-8316, 2001
54. De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447, 2003
55. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR: Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 9: 4792-4801, 2003
56. van Es JH, Barker N, Clevers H: You Wnt some, you lose some: Oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 13: 28-33, 2003
57. Smalley MJ, Dale TC: Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 18: 215-230, 1999
58. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584, 2003